[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345444-105":59,"doc-detail-345444-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-research-progress-and-challenges-of-vaccine-for-human-papillomavirus-associated-cancers-review-future-challenges-and-clinical-trial-strategies","Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers - review - future challenges and clinical trial strategies","","Cervical cancer remains a major cause of cancer-related morbidity in women and is closely driven by persistent infection with high-risk human papillomavirus (HPV), which also contributes to a wider range of malignancies. This review synthesizes clinical-trial research on prophylactic and therapeutic HPV vaccines, then critically evaluates future challenges, including type replacement and implications for long-term vaccine efficacy. It also considers pan-gender and pan-cancer needs by assessing gender-inclusive vaccination for HPV-associated oropharyngeal cancers, and outlines next-generation therapeutic vaccine designs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-research-progress-and-challenges-of-vaccine-for-human-papillomavirus-associated-cancers-review-future-challenges-and-clinical-trial-strategies/345444/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-research-progress-and-challenges-of-vaccine-for-human-papillomavirus-associated-cancers-review-future-challenges-and-clinical-trial-strategies/345444.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main relationship between high-risk HPV and cervical cancer addressed in the review?","Question",{"text":112,"@type":113},"High-risk HPV persistence underpins cervical cancer pathogenesis, and persistent infection is described as a necessary cause. The review also notes that HPV contributes to multiple other cancers beyond the cervix.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do prophylactic and therapeutic HPV vaccines differ in their immune goals?",{"text":117,"@type":113},"Prophylactic vaccines target L1/L2 to induce neutralizing antibodies that prevent infection. Therapeutic vaccines aim to elicit cellular immune responses against existing HPV infections and associated lesions.",{"name":119,"@type":110,"acceptedAnswer":120},"What future challenges and implications for vaccine efficacy does the review highlight?",{"text":121,"@type":113},"The review emphasizes type replacement and its potential consequences for long-term vaccine efficacy. It also discusses implementation barriers that motivate next-generation vaccine strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345444,1790506169,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","REVIEW  \nClinical research progress and challenges of vaccine for human papillomavirus-associated cancers  \nLi Xuea*, Xuhang Lib*, Xiaoman Guoc*, Hui Xingd, and Chuanyu Liue  \naDepartment of Scientific Research, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China; bDepartment of Clinical Laboratory, Xiangyang Hospital of Traditional Chinese Medicine [Xiangyang Institute of Traditional Chinese Medicine], Xiangyang, Hubei Province, China; cDepartment of Clinical Microbiology, Hubei Center for Clinical Laboratory, Wuhan, Hubei Province, China; dDepartment of Obstetrics and Gynaecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China; eCentral Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China  \nABSTRACT  \nAs a major cause of cancer-related morbidity in women, cervical cancer is strongly related to chronic infection by high-risk human papillomavirus (HPV) . This viral persistence also underpins the pathogenesis of a broad spectrum of cancers. In this review, we summarize the research progress of prophylactic and therapeutic HPV vaccines in clinical trials. Furthermore, we present a critical analysis of future challenges, specifically discussing the type replacement phenomenon and its potential implications for long-term vaccine efficacy. We also expand the discourse to a pan-gender and pan-cancer scope, rigorously evaluating the necessity of gender-inclusive vaccination in the context of rising HPV-related oropharyngeal cancers. To overcome real-world implementation barriers, next-generation design strategies, such as chimeric virus-like particles, HPV L2-based vaccines, and heterologous prime-boost immunotherapy regimens for therapeutic HPV vaccines, should be expedited into clinical trials. In summary, this review provides a comprehensive perspective and a forward-looking roadmap for the immunotherapy of HPV-related malignancies.  \nARTICLE HISTORY  \nReceived 14 January 2026 Revised 14 April 2026 Accepted 14 May 2026  \nKEYWORDS  \nHuman papillomavirus; cervical cancer; prophylactic vaccines; therapeutic vaccines; clinical trials  \nIntroduction  \nCervical cancer (CC) is the fourth leading cancer that primarily impairs younger women’s reproductive and sexual health worldwide, with its highest incidence occurring between ages 35 and 44, and a median diagnosis age of 50 y. 1 In 2022, an estimated 660,000 new cases and 350,000 related CC deaths were reported globally.2 The incidence and mortality rates of CC are significantly correlated with the socioeconomic status,3 for example, there is a 3.4-fold difference in the age-standardized incidence of CC between highincome countries (HICs) (3 . 1) and low-and middle-income countries (LMICs) (10 .6) .2 This phenomenon stems from multiple contributing factors, including disparities in access to national human papillomavirus (HPV) vaccination programs, CC screening and treatment services, as well as socioeconomic determinants.4 Decades of researches have confirmed that persistent infection with certain types of HPV is a necessary cause of CC.5 In addition to being a necessary cause of CC, HPV infection also accounts for a substantial fraction of other malignancies, such as anal, head and neck (HAN), vaginal, vulvar, and penile cancers.6 These cancers associated public health burden has driven extensive prevention and therapeutic research.  \nNotably, CC is the first malignancy recognized as susceptible to elimination through widespread vaccination with prophylactic and therapeutic HPV vaccines. Strategies employed in the prevention of this cancer offer a valuable framework for the management of other cancer types.  \nUnlike prophylactic vaccines which stimulate the production of L1/L2-specific neutralizing antibodies to prevent HPV infection, therapeutic vaccines aim to e","cbCaiuXj1o054LCM","https://ap.wps.com/l/cbCaiuXj1o054LCM","pdf",960947,17,"English","# Introduction\n## Burden and epidemiology of cervical cancer\n## Role of high-risk HPV in cancer development\n## Vaccine concepts: prophylactic vs therapeutic\n# Review scope and key focus\n## Clinical progress of prophylactic and therapeutic HPV vaccines\n## Critical challenges: type replacement\n## Pan-gender and pan-cancer evaluation of vaccination necessity\n## Next-generation design strategies for therapeutic vaccines","[{\"question\":\"What is the main relationship between high-risk HPV and cervical cancer addressed in the review?\",\"answer\":\"High-risk HPV persistence underpins cervical cancer pathogenesis, and persistent infection is described as a necessary cause. The review also notes that HPV contributes to multiple other cancers beyond the cervix.\"},{\"question\":\"How do prophylactic and therapeutic HPV vaccines differ in their immune goals?\",\"answer\":\"Prophylactic vaccines target L1/L2 to induce neutralizing antibodies that prevent infection. Therapeutic vaccines aim to elicit cellular immune responses against existing HPV infections and associated lesions.\"},{\"question\":\"What future challenges and implications for vaccine efficacy does the review highlight?\",\"answer\":\"The review emphasizes type replacement and its potential consequences for long-term vaccine efficacy. It also discusses implementation barriers that motivate next-generation vaccine strategies.\"}]","Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers - review - future challenges and clinical trial strategies | PDF",1790057688,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/202f333dd70a675a83fcf6fbe27fbac3.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a69d8fb5fc270b6b606a75b4b3665ec6.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4862f7b8a70e85184e0d02468fdac353.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db24d52434675716ed15048a86ab477c.webp",980,1306]